+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer



Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer



Annals of Oncology 12(5): 599-603



To determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of oxaliplatin administered as hepatic arterial infusion. Patients with isolated hepatic metastases from colorectal cancer were treated every three weeks with increasing doses of oxaliplatin (4 hours; starting dose 25 mg/m2, escalation in steps of 25 mg/m2) in combination with folinic acid (1 hour, 200 mg/m2) and 5-fluorouracil (2 hour, 600 mg/m2). Twenty-one patients (median age, 61 years) have been entered all of whom are fully evaluable. The DLT has been observed at dose level 6, i.e., at 150 mg/m2/cycle and consisted of leucopenia, obliteration of the hepatic artery, and acute pancreatitis. Overall, toxicity mainly consisted of nausea/vomiting (16 of 21 patients), anemia (16 of 21), upper abdominal pain (15 of 21), sensory neuropathy (10 of 21), diarrhea (9 of 21), and thrombocytopenia (9 of 21). The mean PK parameters were: terminal half-life of ultrafiltrable platin, 17.75 +/- 9.29 hours; renal elimination, 48.7% +/- 14.1% of the applied dose; renal clearance 135.55 +/- 45.32 ml/min. The mean area under the plasma-concentration curve (AUC) increased linearly from 3.22 +/- 0.61 microg x h/ml to 18.45 +/- 8.90 microg x h/ml through the first five dose levels (P = 0.0004). Ten of eighteen evaluable patients achieved a complete or partial response (59%). The recommended dose for phase II studies is 125 mg/m2 oxaliplatin.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046970328

Download citation: RISBibTeXText

PMID: 11432616

DOI: 10.1023/a:1011186708754


Related references

Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Anticancer Research 19(6D): 5683-5684, 1999

Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer Results of a phase I and pharmacokinetic study. Onkologie 23(Sonderheft 7): 14, 2000

Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response. Anticancer Research 20(6d): 4973-4975, 2001

Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. Anticancer Research 26(1b): 611-619, 2006

Phase I trial of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (DEX) in combination with systemic oxaliplatin (OXAL), fluorouracil (FU) + leucovorin (LV) after resection of hepatic metastases from colorectal cancer. Journal of Clinical Oncology 23(16_Suppl): 3579-3579, 2016

Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer. In Vivo 20(6a): 743-746, 2007

Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer. In Vivo (Attiki) 20(6A): 743-746, 2006

The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study. Investigational New Drugs 25(5): 479-485, 2007

Hepatic arterial infusion (HAI). Comparison of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres versus 5-fluorouracil and folinic acid in patients with non-resectable colorectal liver metastases. Anticancer Research 26(5b): 3957-3964, 2006

5-fluorouracil, folinic acid and oxaliplatin administered via hepatic arterial infusion as regional second-line therapy for advanced colorectal cancer. Oncology 64(4): 473-474, 2003

5-Fluorouracil, Folinic Acid and Oxaliplatin Administered via Hepatic Arterial Infusion as Regional Second-Line Therapy for Advanced Colorectal Cancer. Oncology 64(4): 473-474, 2003

Definitive results of hybrid chemotherapy with intravenous (iv) oxaliplatin (OXA) and folinic acid (FA), and intra-hepatic infusion (HAI) of 5-fluorouracil (5-FU) in patients with colorectal liver metastases. Journal of Clinical Oncology 23(16_Suppl): 3670-3670, 2016

Hepatic artery infusion of 5-fluorouracil, folinic acid plus oxaliplatin for liver metastasis from colorectal cancer. Final analysis of a phase I/II studay. Journal of Clinical Oncology 23(16_Suppl): 3628-3628, 2016

Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. Cancer ChemoTherapy and Pharmacology 74(5): 1079-1087, 2015

Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. Journal of Clinical Oncology 23(22): 4888-4896, 2005